Welcome to our dedicated page for In8Bio news (Ticker: INAB), a resource for investors and traders seeking the latest updates and insights on In8Bio stock.
IN8bio, Inc. (Nasdaq: INAB) is a clinical-stage biopharmaceutical company whose news flow centers on the development of gamma-delta (γδ) T cell therapies and engagers for cancer and autoimmune diseases. Company press releases and SEC-referenced communications highlight regular updates on clinical trial progress, preclinical data presentations, and corporate developments.
Investors following IN8bio news can expect detailed coverage of its key programs, including INB-100 for leukemias in the post-transplant setting and DeltEx™ Drug-Resistant Immunotherapy (DRI) γδ T cells in INB-200 and INB-400 trials for newly diagnosed glioblastoma. Recent announcements describe extended median progression-free survival in GBM patients receiving repeated doses of DeltEx DRI γδ T cells, favorable safety profiles without dose-limiting toxicities, and multi-center data presented at major scientific meetings such as the American Society of Clinical Oncology (ASCO) and the Society for Neuro-Oncology (SNO).
News items also cover IN8bio’s γδ T cell engager pipeline, including INB-619, a CD19-targeted, pan-γδ T cell engager. The company has reported preclinical data from lupus and systemic lupus erythematosus (SLE) donor models, showing complete B cell depletion with minimal inflammatory cytokine release, and has presented these findings at conferences such as the American College of Rheumatology (ACR) Convergence Meeting and the American Society of Gene & Cell Therapy (ASGCT) Annual Meeting.
In addition, IN8bio issues news releases on its proprietary manufacturing platform, scientific awards, financial results and financing transactions. Readers of INAB news can use this page to monitor clinical milestones, data readouts, scientific conference presentations and material corporate events that the company discloses through press releases and related filings.
IN8bio (Nasdaq: INAB) presented promising preliminary data of INB-200 for glioblastoma at the 2024 ASCO Annual Meeting. The Phase 1 study of INB-200 showed that 92% of patients surpassed the median progression-free survival (PFS) of 7 months achieved with the standard Stupp regimen, with a median follow-up of 11.7 months. Notably, one patient remained progression-free for nearly three years. The study involved 13 patients across three dosing regimens, revealing a favorable safety profile with no serious treatment-related adverse events. All patients completing the full treatment protocol exceeded the median PFS of 7 months, and radiologic evaluations indicated positive treatment effects. IN8bio is now progressing with a Phase 2 study to further evaluate the therapy.
IN8bio, a clinical-stage biopharmaceutical company listed on Nasdaq as INAB, announced its participation in the International Society for Cell & Gene Therapy (ISCT) 2024 from May 28 to June 1 in Vancouver, Canada. IN8bio will present multiple findings on their gamma-delta T cell therapies. Dr. Kate Rochlin, COO, emphasized the significance of these presentations in advancing their proprietary manufacturing platform. Highlights include the INB-400 DeltEx drug-resistant immunotherapy (DRI) multi-center clinical trial and analyses comparing healthy donor and patient-manufactured autologous DeltEx DRI products. These developments are poised to improve cancer patient outcomes by targeting and potentially eradicating cancer cells.
IN8bio announced the upcoming presentation of updated Phase 1 study results for INB-200 at the 2024 ASCO Annual Meeting. INB-200, an autologous Drug Resistant Immunotherapy (DeltEx DRI), is being evaluated as a first-line treatment for newly diagnosed glioblastoma multiforme (GBM). The study involved 23 patients and showed promising progression-free survival (PFS) rates beyond the median expected with standard treatment. There were no dose-limiting toxicities, although some patients experienced adverse events like decreased white blood cell count and fatigue. The presentation will take place on June 1, 2024.
IN8bio (Nasdaq: INAB), a clinical-stage biopharmaceutical company, announced it will present updated interim results from their Phase 1 trial of INB-100 at the upcoming European Hematology Association (EHA) 2024 Congress in Madrid, June 13-16. INB-100 is a gamma-delta T cell therapy aimed at increasing survival and reducing cancer recurrence in leukemia patients post-haploidentical stem cell transplantation, without severe graft-versus-host disease. The presentation will be held on June 14, 2024, at 10:00 a.m. CEST by Dr. Joseph P. McGuirk. Abstracts are accessible on the EHA website, and the poster will be available on IN8bio's site following the session.
IN8bio presented details about its robust and reproducible gamma-delta T cell therapy manufacturing platform at ASGCT 2024. The data demonstrate significant advancements in the characterization of gamma-delta T cell-based therapies, showing increased potency, effector functions, and trafficking capabilities. The study evaluated T cell products from healthy donors and GBM patients, revealing consistent profiles and gene expression changes throughout the manufacturing process.
IN8bio, Inc. (Nasdaq: INAB) reported financial results for Q1 2024, highlighting progress in gamma-delta T cell programs. Key points include preclinical data on nsCAR platform targeting cancer cells, peer-reviewed publication on DeltEx Drug Resistant Immunotherapy for GBM, and dosing first patient in Phase 2 clinical trial. Financially, R&D expenses increased to $4.9 million, G&A expenses were $3.7 million, net loss was $8.6 million, and cash position stood at $13.0 million.
IN8bio, Inc. (Nasdaq: INAB) has dosed the first patient in a Phase 2 clinical trial of INB-400 for newly diagnosed glioblastoma multiforme (GBM). INB-400 is an autologous gamma-delta T cell therapy genetically engineered to survive chemotherapy and enhance cancer cell killing. The trial, expected to enroll up to 40 patients, aims to evaluate safety, tolerability, and overall survival rate at 12 months. INB-400 was granted Orphan Drug Designation in 2023 and is designed to work alongside standard-of-care treatments like temozolomide.
Summary not available.
Summary not available.
Summary not available.